Fundraising to bolster its positioning
Destiny have announced a conditional fundraising at 50p per share that includes a placing, subscription and Open Offer that could in total raise up to £7.0m. With the raised level of uncertainty in the markets and the ongoing partnering of Destiny’s two Phase 3-ready assets, the Board decided to proceed with the fundraising so as not to delay the activities on its two lead assets. Just as importantly, reinforcing its balance sheet should strengthen its negotiating position with potential partners.With the ongoing ‘risk-off’ reaction to the war in Ukraine, and the potential for equity markets to suffer further, Destiny’s Board have sensibly decided to proceed with a fundraising to finalise the regulatory plans and secure the continuation of the preparation for the partnering of its two Phase 3-ready assets – NTCD-M3 for the prevention of Clostridioides difficile infections, and XF-73 for the prevention of post-surgical staphylococcal infections.
Our fair value of Destiny Pharma stood at £187.9m or 314p per share, but the dilution of the full conditional fundraising and the final amount raised net of costs will undoubtedly have an effect. We plan to publish revised numbers after the General Meeting on March 28.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.